Drug intelligence / Profile preview

influenza A (H1N1) vaccine (Jiangsu CDC)

Development stage
Approved
Lead developer
Sinovac Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

This is an inactivated, split-virion, non-adjuvanted monovalent vaccine developed for the prevention of influenza A (H1N1) virus infection. Developed and evaluated by the Jiangsu Province Centers for Disease Control and Prevention, the vaccine contains 15 μg of hemagglutinin antigen. It was specifically studied in a prospective cohort and stratified controlled clinical trial involving pregnant women in China to assess safety and immunogenicity. The vaccine demonstrated a high seroconversion rate of 90.4% and was found to be safe for both the mothers and fetal growth, with a low adverse event rate. It was part of the public health response in China following the 2009 H1N1 pandemic.

Other names
split-virion, non-adjuvanted H1N1 vaccineinactivated H1N1 vaccine (Jiangsu CDC)influenza A (H1N1) vaccine-Jiangsu Province Centers for Disease Control and Prevention-influenza A (H1N1)
02

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on influenza A (H1N1) vaccine (Jiangsu CDC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza A (H1N1) vaccine (Jiangsu CDC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call